1. **The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale**


2. **Gender differences among patients with acute coronary syndromes undergoing percutaneous coronary intervention in the American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR)**

   Akhter, N., et al.


3. **Comparative trends in guidelines adherence among patients with non-ST-segment elevation acute coronary syndromes treated with invasive versus conservative management strategies: Results from the CRUSADE quality improvement initiative**

   Amsterdam, E.A., et al.


4. **Serial bedside B-type natriuretic peptide strongly predicts prognosis in acute coronary syndrome independent of echocardiographic abnormalities**

   Ang, D.S., et al.


5. **Blood pressure paradox in patients with non-ST-segment elevation acute coronary syndromes: results from 139,194 patients in the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association Guidelines (CRUSADE) quality improvement initiative**

   Bangalore, S., et al.


6. **Evidence-based medication use among Chinese patients with acute coronary
syndromes at the time of hospital discharge and 1 year after hospitalization: results from the Clinical Pathways for Acute Coronary Syndromes in China (CPACS) study


9. Adding intravenous unfractionated heparin to standard enoxaparin causes excessive anticoagulation not detected by activated clotting time: results of the STACK-on to ENOXaparin (STACKENOX) study


10. Validation of the Global Registry of Acute Coronary Event (GRACE) risk score for in-hospital mortality in patients with acute coronary syndrome in Canada


11. The expanded Global Registry of Acute Coronary Events: baseline
Characteristics, management practices, and hospital outcomes of patients with acute coronary syndromes
Goodman, S.G., et al.

12. Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study
Han, Y., et al.

13. Use of beta-blockers and effects on heart rate and blood pressure post-acute coronary syndromes: are we on target?
Herman, M., et al.

14. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial
James, S., et al.

15. Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: outcomes and treatment effect across different levels of risk

16. Validity of a risk-prediction tool for hospital mortality: the Global Registry of Acute Coronary Events
17. Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRIal to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibition with prasugrel (TRITON)-Thrombolysis in Myocardial Infarction (TIMI) 38 substudy


18. Temporal trends and patterns of early clopidogrel use across the spectrum of acute coronary syndromes


20. Impact of female gender and transradial coronary stenting with maximal antiplatelet therapy on bleeding and ischemic outcomes


21. Incidence, distribution, and prognostic impact of occluded culprit arteries among patients with non-ST-elevation acute coronary syndromes undergoing diagnostic angiography
22. **Detection of myocardial injury in patients with unstable angina using a novel nanoparticle cardiac troponin I assay: observations from the PROTECT-TIMI 30 Trial**


23. **Randomized trial comparing 600- with 300-mg loading dose of clopidogrel in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: results of the Platelet Responsiveness to Aspirin and Clopidogrel and Troponin Increment after Coronary intervention in Acute coronary Lesions (PRACTICAL) Trial**

Yong, G., et al.

24. **Rationale and design of China intensive lipid lowering with statins in acute coronary syndrome: the CHILLAS study**

Zhao, S.P., et al.

25. **Effect of cholesterol crystals on plaques and intima in arteries of patients with acute coronary and cerebrovascular syndromes**

Abela, G.S., et al.

26. **Relation of patient age and mortality to reported contraindications to early beta-blocker use for non-ST-elevation acute coronary syndrome**

Allen LaPointe, N.M., et al.

27. Safety of contrast in stress echocardiography in stable patients and in patients with suspected acute coronary syndrome but negative 12-hour troponin
Anantharam, B., et al.

28. Influence of age on use of cardiac catheterization and associated outcomes in patients with non-ST-elevation acute coronary syndromes

29. Comparison of outcomes in patients \( \geq \)70 years versus <70 years after transradial coronary stenting with maximal antiplatelet therapy for acute coronary syndrome
Bagur, R., et al.

30. Usefulness of age and gender in the early triage of patients with acute chest pain having cardiac computed tomographic angiography
Bamberg, F., et al.

31. Effect of blood hematocrit and erythrocyte deformability on adenosine 5'-diphosphate platelet reactivity in patients with acute coronary syndromes on dual antiplatelet therapy
Cecchi, E., et al.
32. Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients
Cuisset, T., et al.

33. Patient characteristics associated with the choice of triple antithrombotic therapy in acute coronary syndromes
Depta, J.P., et al.

34. Impact of admission glucose level and presence of diabetes mellitus on mortality in patients with non-ST-segment elevation acute coronary syndrome treated conservatively
Dziewierz, A., et al.

35. Comparison of men and women with acute coronary syndrome in six Middle Eastern countries

36. Usefulness of diabetes mellitus to predict long-term outcomes in patients with unstable angina pectoris
Farkouh, M.E., et al.

37. Timing and duration of myocardial ischemia on Holter monitoring following percutaneous coronary intervention and their association with clinical outcomes (a PROTECT-TIMI 30 Substudy Analysis)
Gibson, C.M., et al.
38. **Prehospital Delay in Patients With Acute Coronary Syndromes (from the Global Registry of Acute Coronary Events [GRACE])**
Goldberg, R.J., et al.

39. **Thrombocytopenia in patients with an acute coronary syndrome (from the Global Registry of Acute Coronary Events [GRACE])**

40. **Comparison of treatment and outcome of acute coronary syndrome in patients with versus patients without diabetes mellitus**
Hasin, T., et al.

41. **Prognostic value of admission fasting glucose levels in patients with acute coronary syndrome**
Kolman, L., et al.

42. **Impact of gender and antithrombin strategy on early and late clinical outcomes in patients with non-ST-elevation acute coronary syndromes (from the ACUITY trial)**

43. **Prognostic impact of types of atrial fibrillation in acute coronary syndromes**
44. Usefulness of elevations in serum choline and free F2-isoprostane to predict 30-day cardiovascular outcomes in patients with acute coronary syndrome

LeLeiko, R.M., et al.

45. Comparison of site-reported and core laboratory-reported creatine kinase-MB values in non-ST-segment elevation acute coronary syndrome (from the international trial SYNERGY)

Linefsky, J.P., et al.

46. Severity of coronary arterial stenoses responsible for acute coronary syndromes

Manoharan, G., et al.

47. Predictors of early discontinuation of evidence-based medicine after acute coronary syndrome

Melloni, C., et al.

48. Anemia for risk assessment of patients with acute coronary syndromes

Meneveau, N., et al.

49. Effect of culprit-lesion remodeling versus plaque rupture on three-year outcome
50. **Current use of beta blockers in patients with reactive airway disease who are hospitalized with acute coronary syndromes**
Okura, H., et al.  

51. **Comparison of the effects of ramipril versus telmisartan on high-sensitivity C-reactive protein and endothelial progenitor cells after acute coronary syndrome**
Porto, I., et al.  

52. **Effectiveness of myocardial perfusion scintigraphy to predict coronary anatomy in patients with non-ST elevation acute coronary syndrome**
Potter, B.J., et al.  

53. **Acute effects of statin therapy on coronary atherosclerosis following an acute coronary syndrome**
Rodes-Cabau, J., et al.  

54. **Arterial access-site-related outcomes of patients undergoing invasive coronary procedures for acute coronary syndromes (from the ComPaRison of Early Invasive and Conservative Treatment in Patients With Non-ST-Elevation Acute Coronary Syndromes [PRESTO-ACS] Vascular Substudy)**
Sciahbasi, A., et al.  
55. **Relation of death within 90 days of non-ST-elevation acute coronary syndromes to variability in electrocardiographic morphology**

Syed, Z., et al.

56. **Comparison of drug-eluting stents and bare-metal stents for the treatment of unprotected left main coronary artery disease in acute coronary syndromes**

Tamburino, C., et al.

57. **Seasonal variation in lipids in patients following acute coronary syndrome on fixed doses of Pravastatin (40 mg) or Atorvastatin (80 mg) (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22 [PROVE IT-TIMI 22] Study)**

Tung, P., et al.

58. **Relation of body mass index to mortality after development of heart failure due to acute coronary syndrome**

Wu, A.H., et al.

59. **Comparison of usefulness of simvastatin 20 mg versus 80 mg in preventing contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention**

Xinwei, J., et al.
60. Clinical significance of borderline elevated troponin I levels across different assays in patients with suspected acute coronary syndrome
Zahid, M., et al.

61. Prognosis of patients suffering an acute coronary syndrome while already under chronic clopidogrel therapy
Bonello, L., et al.

62. Effectiveness of the transradial approach to reduce bleedings in patients undergoing urgent coronary angioplasty with GPIIb/IIIa inhibitors for acute coronary syndromes
De Carlo, M., et al.

63. Is computed tomography coronary angiography the most accurate and effective noninvasive imaging tool to evaluate patients with acute chest pain in the emergency department? CT coronary angiography is the most accurate and effective noninvasive imaging tool for evaluating patients presenting with chest pain to the emergency department: antagonist viewpoint
Hendel, R.C.

64. Is computed tomography coronary angiography the most accurate and effective noninvasive imaging tool to evaluate patients with acute chest pain in the emergency department? CT coronary angiography is the most accurate and effective noninvasive imaging tool for evaluating patients presenting with chest pain to the emergency department
Hoffmann, U. and F. Bamberg
65. Early stent thrombosis in patients with acute coronary syndromes treated with drug-eluting and bare metal stents: the Acute Catheterization and Urgent Intervention Triage Strategy trial
Aoki, J., et al.

66. Quality of care for acute coronary syndrome patients with known atherosclerotic disease: results from the Get With the Guidelines Program
Brilakis, E.S., et al.

67. Soluble CXCL16 predicts long-term mortality in acute coronary syndromes

68. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up
Marcucci, R., et al.

69. Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial

70. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the
71. **Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score**

Subherwal, S., et al.

72. **Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in contemporary clinical practice**

Wang, T.Y., et al.

73. **Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure**

Abrahamsson, P., et al.

74. **Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes**

Budaj, A., et al.

75. **Diverging associations of an intended early invasive strategy compared with actual revascularization, and outcome in patients with non-ST-segment elevation acute coronary syndrome: the problem of treatment selection bias**

76. **Prognostic value of circulating chromogranin A levels in acute coronary syndromes**  

77. **Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial**  
Mehran, R., et al.  

78. **Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial**  
Michelson, A.D., et al.  

79. **Expression of stromal-cell-derived factor-1 on circulating platelets is increased in patients with acute coronary syndrome and correlates with the number of CD34+ progenitor cells**  
Stellos, K., et al.  

80. **Lipid-rich plaque and myocardial perfusion after successful stenting in patients with non-ST-segment elevation acute coronary syndrome: an optical coherence tomography study**  
Tanaka, A., et al.  
81. Temporal management patterns and outcomes of non-ST elevation acute coronary syndromes in patients with kidney dysfunction

82. Enhanced expression of haemoglobin scavenger receptor in accumulated macrophages of culprit lesions in acute coronary syndromes
Yunoki, K., et al.

83. A comparison between B-type natriuretic peptide, global registry of acute coronary events (GRACE) score and their combination in ACS risk stratification
Ang, D.S., et al.

84. Predicting freedom from clinical events in non-ST-elevation acute coronary syndromes: the Global Registry of Acute Coronary Events

85. Sex-related differences in the presentation, treatment and outcomes among patients with acute coronary syndromes: the Global Registry of Acute Coronary Events
Dey, S., et al.

86. Evaluation of risk scores for risk stratification of acute coronary syndromes in the Myocardial Infarction National Audit Project (MINAP) database
Gale, C.P., et al.
87. Impact of acute and chronic risk factors on use of evidence-based treatments in patients in Australia with acute coronary syndromes
Joynt, K.E., et al.

88. Simple point-of-care risk stratification in acute coronary syndromes: the AMIS model
Kurz, D.J., et al.

89. Secondhand smoke exposure and survival following acute coronary syndrome: prospective cohort study of 1261 consecutive admissions among never-smokers
Pell, J.P., et al.

90. Prognostic value of coronary revascularisation-related myocardial injury: a cardiac magnetic resonance imaging study
Rahimi, K., et al.

91. Choice of secondary prevention improves risk factors after acute coronary syndrome: 1-year follow-up of the CHOICE (Choice of Health Options In prevention of Cardiovascular Events) randomised controlled trial
Redfern, J., et al.

92. Immediate versus deferred coronary angioplasty in non-ST-segment elevation
93. *Pregnancy in high risk cardiac conditions*
Roos-Hesselink, J.W., J.J. Duvekot, and S.A. Thorne

94. *Delay to angiography and outcomes following presentation with high-risk, non-ST-elevation acute coronary syndromes: results from the Global Registry of Acute Coronary Events*
Swanson, N., et al.

95. *Chest pain in the emergency department: role of cardiac imaging*
Wackers, F.J.

96. *Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial*
Dangas, G., et al.

97. *Prognostic value of biomarkers during and after non-ST-segment elevation acute coronary syndrome*
98. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial


100. Coronary computed tomography angiography for early triage of patients with acute chest pain: the ROMICAT (Rule Out Myocardial Infarction using Computer Assisted Tomography) trial

101. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial

102. Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial

103. Computed tomographic angiography characteristics of atherosclerotic plaques subsequently resulting in acute coronary syndrome

104. Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial

105. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis

106. Prognostic significance of periprocedural versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with acute coronary syndromes: an analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial

107. Ischemia detected on continuous electrocardiography after acute coronary syndrome: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With
Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction 36) trial
Scirica, B.M., et al.

108. Normal plasma levels of cardiac troponin I measured by the high-sensitivity cardiac troponin I access prototype assay and the impact on the diagnosis of myocardial ischemia
Venge, P., et al.

109. Early statin therapy in acute coronary syndromes: the successful cycle of evidence, guidelines, and implementation
Waters, D.D. and I. Ku

110. Sex differences in mortality following acute coronary syndromes
Berger, J.S., et al.

111. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome
Ho, P.M., et al.

112. Immediate vs delayed intervention for acute coronary syndromes: a randomized clinical trial
Montalescot, G., et al.
113. *Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial*
Mega, J.L., et al.

114. *Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial*
Sabatine, M.S., et al.

115. *Early versus delayed, provisional eptifibatide in acute coronary syndromes*
Giugliano, R.P., et al.

116. *Early versus delayed invasive intervention in acute coronary syndromes*

117. *Ticagrelor versus clopidogrel in patients with acute coronary syndromes*
Wallentin, L., et al.

118. *Age-related differences in virtual histology-intravascular ultrasound findings in patients with coronary artery disease*
Hong, Y.J., et al.
119. Anti-apolipoprotein A-1 IgG as an independent cardiovascular prognostic marker affecting basal heart rate in myocardial infarction
Vuilleumier, N., et al.
Eur Heart J, 2010.

120. Aspects on the intensity and the relief of pain in the prehospital phase of acute coronary syndrome: experiences from a randomized clinical trial
Zedigh, C., et al.

121. Aspirin administration in ED patients who presented with undifferentiated chest pain: age, race, and sex effects
Takakuwa, K.M., F.S. Shofer, and J.E. Hollander

122. Assessment of ischemia-modified albumin levels for emergency room diagnosis of acute coronary syndrome
Int J Cardiol, 2010.

123. Characteristics and outcome of patients with acute coronary syndrome and normal or near-normal coronary angiography
Minha, S., et al.
Coron Artery Dis, 2010.

124. Clinical outcome after acute coronary syndrome in Japanese patients: An observational cohort study
Nakamura, M., et al.
125. A comparison of clinical presentations, angiographic patterns and outcomes of in-stent restenosis between bare metal stents and drug eluting stents
Rathore, S., et al.

126. Coronary Artery Calcium Scoring in the Emergency Department: Identifying Which Patients With Chest Pain Can Be Safely Discharged Home
Nabi, F., et al.

127. Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? A randomized trial
Toh, S., et al.

128. Coronary Revascularization Strategy for ST Elevation Myocardial Infarction with Multivessel Disease: Experience and Results at 1-Year Follow-Up
Mohamad, T., et al.

129. Coronary score adds prognostic information for patients with acute coronary syndrome
Huang, G., et al.

130. Correlation of thrombolysis in myocardial infarction (TIMI) risk score with extent of coronary artery disease in patients with acute coronary syndrome
131. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38
Mahoney, E.M., et al.

132. CYP1A1 MSPI (T6235C) gene polymorphism is associated with mortality in acute coronary syndrome patients
Jarvis, M.D., et al.

133. Differences in mortality in acute coronary syndrome symptom clusters
Riegel, B., et al.

134. Differential levels of circulating progenitor cells in acute coronary syndrome patients with a first event versus patients with recurring events
Porto, I., et al.
Int J Cardiol, 2010.

135. Effects of labetalol on hemodynamic parameters and soluble biomarkers of inflammation in acute coronary syndrome in patients with active cocaine use
Hoskins, M.H., et al.
136. Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial
Rasmussen, K., et al.

137. Elevated CK-MB values after routine angioplasty predicts worse long-term prognosis in low-risk patients
Vikenes, K., et al.

Niccoli, G., et al.
Atherosclerosis, 2010.

139. Factors related to heart rupture in acute coronary syndromes in the Global Registry of Acute Coronary Events
Lopez-Sendon, J., et al.
Eur Heart J, 2010.

140. Gender differences in the treatment of non-ST-segment elevation myocardial infarction
Tavris, D., et al.

141. Gender perspective on risk factors, coronary lesions and long-term outcome in young patients with ST-elevation myocardial infarction
Lawesson, S.S., et al.
142. [Peculiarities of Dynamics and Prognostic Value of NT-proBNP Level in Different Variants of Treatment of Patients With Acute Coronary Syndrome.]
Shreider, E.V., et al.

143. Plasma cystatin C for prediction of 1-year cardiac events in Mediterranean patients with non-ST elevation acute coronary syndrome
Taglieri, N., et al.

144. Plasma levels of Hsp70 and anti-Hsp70 antibody predict risk of acute coronary syndrome
Zhang, X., et al.

145. Postprocedural hyperglycemia in ST elevation myocardial infarction submitted to percutaneous coronary intervention: a prognostic indicator and a marker of metabolic derangement
Lazzeri, C., et al.

146. Pre-hospital ECG for acute coronary syndrome in urban India: A cost-effectiveness analysis
Schulman-Marcus, J., D. Prabhakaran, and T.A. Gaziano

147. Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial
148. *Prognostic value of myeloperoxidase in coronary artery disease: comparison of unstable and stable angina patients*  
Roman, R.M., et al.  
Coron Artery Dis, 2010.  

149. *Psoriasis may not be an independent risk factor for acute ischemic heart disease hospitalizations: results of a large population-based Dutch cohort*  
Wakkee, M., R.M. Herings, and T. Nijsten  

150. *Relationship between serum vasoactive factors and plaque morphology in patients with non-ST-segment elevated acute coronary syndrome*  
Lu, Y.F., S.Z. Lu, and Y.D. Chen  

151. *Subclinical myocardial necrosis and cardiovascular risk in stable patients undergoing elective cardiac evaluation*  
Tang, W.H., et al.  

152. *Towards risk stratification in systemic atherosclerosis: value of myocardial function and viability imaging as an adjunct to MR angiography*  
Seeger, A., et al.  
153. Treatment with 5-Lipoxygenase Inhibitor VIA-2291 (Atreleuton) in Patients with Recent Acute Coronary Syndrome

Tardif, J.C., et al.